The hypereosinophilic syndrome revisited.
Clinical and biological features of patients with the idiopathic hypereosinophilic syndrome (HES) are heterogeneous. Recent evidence suggests at least two distinct underlying hematological disorders involving myeloid and lymphoid cells, respectively. We therefore suggest that the term idiopathic should be abandoned in the classification of HES. This review defines the "myeloproliferative" and "lymphocytic" variants of the HES and addresses the management of each variant, focusing on diagnosis and treatment of the newly identified lymphocytic variant.
Roufosse
Florence
F
Department of Internal Medicine Université Libre de Bruxelles, B-1070 Brussels, Belgium. froufoss@ulb.ac.be
Cogan
Elie
E
Goldman
Michel
M
D016207:Cytokines / Q000097:blood; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D007073:Immunoglobulin E / Q000097:blood; D009196:Myeloproliferative Disorders / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D016207:Cytokines; D007073:Immunoglobulin E